|
|
1 | (2) |
|
|
3 | (132) |
|
The Science of Bioterrorism: HHS Preparedness |
|
|
|
Director, Office of Public Health Preparedness, Department of Health and Human Services |
|
|
9 | (14) |
|
|
Metropolitan Medical Response System |
|
|
10 | (1) |
|
National Disaster Medical System (NDMS) |
|
|
11 | (1) |
|
National Pharmaceutical Stockpile |
|
|
11 | (2) |
|
CDC Surveillance and Prevention Efforts |
|
|
13 | (1) |
|
CDC and ATSDR Remediation Support Activities |
|
|
14 | (2) |
|
Food and Drug Administration |
|
|
16 | (1) |
|
National Institutes of Health |
|
|
17 | (2) |
|
|
19 | (4) |
|
Frequently Asked Questions: Bioterrorism Concerns After September 11 |
|
|
|
The Johns Hopkins Center for Civilian Biodefense Strategies |
|
|
23 | (4) |
|
Funding for Bioterrorism Preparedness and Response |
|
|
|
Resolution, U.S. Congress |
|
|
27 | (4) |
|
Bioterrorism Public Health Advisories and Guidelines |
|
|
|
Centers for Disease Control and Prevention (CDC) |
|
|
31 | (1) |
|
|
31 | (27) |
|
|
31 | (1) |
|
|
32 | (1) |
|
|
32 | (2) |
|
|
34 | (3) |
|
|
37 | (2) |
|
|
39 | (2) |
|
|
41 | (1) |
|
|
42 | (4) |
|
|
46 | (1) |
|
|
47 | (1) |
|
|
48 | (3) |
|
|
51 | (1) |
|
|
51 | (5) |
|
|
56 | (2) |
|
Biological and Chemical Terrorism: Strategic Plan for Preparedness and Response |
|
|
58 | (21) |
|
Recommendations of the CDC Strategic Planning Workgroup |
|
|
59 | (1) |
|
|
59 | (2) |
|
U.S. Vulnerability to Biological and Chemical Terrorism |
|
|
61 | (1) |
|
Overt Versus Covert Terrorist Attacks |
|
|
61 | (1) |
|
Focusing Preparedness Activities |
|
|
62 | (1) |
|
|
63 | (3) |
|
Partnerships and Implementation |
|
|
66 | (1) |
|
|
66 | (1) |
|
|
67 | (12) |
|
Children and Anthrax: A Fact Sheet for Clinicians |
|
|
79 | (5) |
|
|
80 | (1) |
|
|
80 | (1) |
|
Drug Recommendations for Pediatric Anthrax Cases |
|
|
81 | (3) |
|
Considerations for Distinguishing Influenza-Like Illness from Inhalational Anthrax |
|
|
84 | (5) |
|
Epidemiologic Considerations |
|
|
84 | (1) |
|
|
85 | (1) |
|
|
85 | (4) |
|
Epidemiology of Bioterrorism |
|
|
89 | (5) |
|
|
89 | (1) |
|
|
90 | (1) |
|
|
90 | (1) |
|
|
91 | (1) |
|
Recommendations for Preparedness |
|
|
92 | (2) |
|
Health Advisory: How to Recognize and Handle a Suspicious Package or Envelope |
|
|
94 | (3) |
|
Identifying Suspicious Packages and Envelopes |
|
|
94 | (3) |
|
Health Advisory: Recommendations for Protecting Workers from Exposure to Bacillus anthracis in Work Sites Where Mail Is Handled or Processed |
|
|
97 | (5) |
|
Health Advisory: Use of Ciprofloxacin or Doxycycline for Postexposure Prophylaxis for Prevention of Inhalation Anthrax |
|
|
102 | (1) |
|
Interim Guidelines for Investigation of and Response to Bacillus Anthracis Exposures |
|
|
103 | (5) |
|
|
103 | (1) |
|
|
104 | (1) |
|
|
105 | (1) |
|
|
105 | (1) |
|
Antimicrobial Prophylaxis |
|
|
106 | (1) |
|
|
107 | (1) |
|
Protecting Investigators Performing Environmental Sampling for Bacillus anthracis: Personal Protective Equipment |
|
|
108 | (3) |
|
Recognition of Illness Associated with the Intentional Release of a Biologic Agent |
|
|
111 | (6) |
|
|
111 | (2) |
|
Clinical Laboratory Personnel |
|
|
113 | (1) |
|
Infection-Control Professionals |
|
|
114 | (1) |
|
|
114 | (3) |
|
Updated Recommendations for Antimicrobial Prophylaxis among Asymptomatic Pregnant Women after Exposure to Bacillus anthracis |
|
|
117 | (2) |
|
Use of Onsite Technologies for Rapidly Assessing Environmental Bacillus Anthracis Contamination on Surfaces in Buildings |
|
|
119 | (2) |
|
Vaccinia (Smallpox) Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001 |
|
|
121 | (14) |
|
Routine Nonemergency Vaccine Use |
|
|
121 | (1) |
|
Routine Nonemergency Revaccination |
|
|
122 | (1) |
|
Side Effects and Adverse Reactions |
|
|
122 | (1) |
|
Treatment for Vaccinia Vaccine Complications |
|
|
122 | (1) |
|
Other Treatment Options for Vaccinia Vaccine Complications |
|
|
123 | (1) |
|
Consultation Regarding Complications of Vaccinia Vaccine |
|
|
123 | (2) |
|
|
125 | (1) |
|
|
126 | (1) |
|
|
127 | (1) |
|
|
128 | (1) |
|
|
128 | (2) |
|
Infection Control Measures |
|
|
130 | (2) |
|
Vaccinia Immunoglobulin for Prophylaxis and Treatment of Adverse Reactions during a Smallpox Emergency |
|
|
132 | (3) |
|
News, Communications, and Internet Research |
|
|
135 | (12) |
|
News Sources and Bulletins |
|
|
135 | (7) |
|
|
142 | (3) |
|
Literature Searches and Online Libraries |
|
|
145 | (1) |
|
|
145 | (2) |
|
|
147 | (12) |
|
|
147 | (5) |
|
|
152 | (1) |
|
Weapons of Mass Destruction |
|
|
153 | (1) |
|
|
154 | (3) |
|
|
157 | (2) |
|
Public Policy, Preparedness, and Response |
|
|
159 | (18) |
|
Public Policy Guidelines, Conventions, and Analysis |
|
|
159 | (2) |
|
Public Preparedness and Response |
|
|
161 | (12) |
|
Legislation and Legal Issues |
|
|
173 | (4) |
|
Clinical Resources on Bioterrorism |
|
|
177 | (10) |
|
Guidelines and Consensus Statements |
|
|
177 | (4) |
|
|
181 | (2) |
|
|
183 | (2) |
|
Immunization and Vaccines |
|
|
185 | (2) |
|
Health and Safety Guidelines |
|
|
187 | (4) |
|
|
191 | (18) |
|
|
191 | (1) |
|
|
191 | (5) |
|
|
196 | (3) |
|
|
199 | (1) |
|
|
199 | (2) |
|
|
201 | (1) |
|
|
202 | (3) |
|
|
205 | (1) |
|
|
206 | (3) |
|
|
209 | (4) |
|
|
213 | (2) |
|
|
215 | (2) |
|
|
217 | (6) |
|
|
217 | (3) |
|
Post-Traumatic Stress Disorder |
|
|
220 | (3) |
|
Agencies, Organizations, and Centers |
|
|
223 | (40) |
|
U.S. Government Agencies and Programs |
|
|
223 | (10) |
|
U.S. Military Agencies and Programs |
|
|
233 | (9) |
|
|
242 | (10) |
|
Research and Policy Centers |
|
|
252 | (7) |
|
|
259 | (4) |
|
Public Health Resources on the Internet |
|
|
263 | (26) |
|
|
263 | (1) |
|
|
263 | (4) |
|
Hotlines and Altering Services |
|
|
267 | (2) |
|
Online Texts and Tutorials |
|
|
269 | (4) |
|
Mailing Lists and Discussion Forums |
|
|
273 | (1) |
|
Education and Training Resources |
|
|
274 | (6) |
|
|
280 | (4) |
|
|
284 | (5) |
|
|
289 | (2) |
|
Web Site and Topical Index |
|
|
291 | |